CN103272170B - Application of rhodiola rosea compound composite in preparing drug for treating duodenal ulcer - Google Patents
Application of rhodiola rosea compound composite in preparing drug for treating duodenal ulcer Download PDFInfo
- Publication number
- CN103272170B CN103272170B CN201310260997.XA CN201310260997A CN103272170B CN 103272170 B CN103272170 B CN 103272170B CN 201310260997 A CN201310260997 A CN 201310260997A CN 103272170 B CN103272170 B CN 103272170B
- Authority
- CN
- China
- Prior art keywords
- parts
- herba
- drug
- preparation
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 61
- 229940079593 drug Drugs 0.000 title claims abstract description 33
- 208000000718 duodenal ulcer Diseases 0.000 title claims abstract description 19
- 150000001875 compounds Chemical class 0.000 title claims abstract description 7
- 244000042430 Rhodiola rosea Species 0.000 title abstract 3
- 235000003713 Rhodiola rosea Nutrition 0.000 title abstract 3
- 239000002131 composite material Substances 0.000 title description 2
- 238000002360 preparation method Methods 0.000 claims description 22
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 6
- 241001529553 Scoparia <angiosperm> Species 0.000 claims description 4
- 241001165494 Rhodiola Species 0.000 claims description 2
- 239000003405 delayed action preparation Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 10
- 239000000796 flavoring agent Substances 0.000 abstract description 5
- 235000019634 flavors Nutrition 0.000 abstract description 5
- 235000003261 Artemisia vulgaris Nutrition 0.000 abstract description 2
- 240000002505 Pogostemon cablin Species 0.000 abstract description 2
- 235000011751 Pogostemon cablin Nutrition 0.000 abstract description 2
- 244000197580 Poria cocos Species 0.000 abstract description 2
- 235000008599 Poria cocos Nutrition 0.000 abstract description 2
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 abstract 1
- 235000003097 Artemisia absinthium Nutrition 0.000 abstract 1
- 240000001851 Artemisia dracunculus Species 0.000 abstract 1
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 abstract 1
- 241000132012 Atractylodes Species 0.000 abstract 1
- 240000002943 Elettaria cardamomum Species 0.000 abstract 1
- 240000001949 Taraxacum officinale Species 0.000 abstract 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000001138 artemisia absinthium Substances 0.000 abstract 1
- 235000005300 cardamomo Nutrition 0.000 abstract 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 210000000582 semen Anatomy 0.000 description 14
- 208000002193 Pain Diseases 0.000 description 8
- 230000036407 pain Effects 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 235000012054 meals Nutrition 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 208000025865 Ulcer Diseases 0.000 description 5
- 230000036528 appetite Effects 0.000 description 5
- 235000019789 appetite Nutrition 0.000 description 5
- 231100000397 ulcer Toxicity 0.000 description 5
- 206010000087 Abdominal pain upper Diseases 0.000 description 4
- 241000208340 Araliaceae Species 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 4
- 235000003140 Panax quinquefolius Nutrition 0.000 description 4
- 208000008469 Peptic Ulcer Diseases 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 238000001839 endoscopy Methods 0.000 description 4
- 235000008434 ginseng Nutrition 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 208000011906 peptic ulcer disease Diseases 0.000 description 4
- 206010023126 Jaundice Diseases 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 210000001198 duodenum Anatomy 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 235000003069 Artemisia scoparia Nutrition 0.000 description 2
- 241001249148 Artemisia scoparia Species 0.000 description 2
- 235000011273 Benincasa Nutrition 0.000 description 2
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 2
- 244000192528 Chrysanthemum parthenium Species 0.000 description 2
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 241000555712 Forsythia Species 0.000 description 2
- 240000008669 Hedera helix Species 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 241000498779 Myristica Species 0.000 description 2
- 206010030302 Oliguria Diseases 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 241001349593 Praecitrullus Species 0.000 description 2
- 241000545442 Radix Species 0.000 description 2
- 208000012886 Vertigo Diseases 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000000589 cicatrix Anatomy 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000008384 feverfew Nutrition 0.000 description 2
- 206010016766 flatulence Diseases 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000889 vertigo Toxicity 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- -1 1 time Substances 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 235000003826 Artemisia Nutrition 0.000 description 1
- 241000092665 Atractylodes macrocephala Species 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 208000001387 Causalgia Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 241000220284 Crassulaceae Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010017865 Gastritis erosive Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000997135 Rhodiola crenulata Species 0.000 description 1
- 241000576755 Sclerotia Species 0.000 description 1
- 241000238371 Sepiidae Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000245665 Taraxacum Species 0.000 description 1
- 241000292546 Taraxacum mongolicum Species 0.000 description 1
- 241001661641 Verrucosa Species 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 244000030166 artemisia Species 0.000 description 1
- 235000009052 artemisia Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 208000015864 chronic erosive gastritis Diseases 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 238000002575 gastroscopy Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 210000004203 pyloric antrum Anatomy 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 210000002417 xiphoid bone Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an application of a rhodiola rosea compound drug in preparing a drug for treating duodenal ulcer. The drug is prepared by the following active ingredients by in parts by weight: 4.2-7.2 parts of rhodiola rosea, 14-26 parts of poria cocos, 10.5-19.5 parts of dandelion, 10.5-19.5 parts of oriental wormwood, 10.5-19.5 parts of bighead atractylodes rhizome, 7-13 parts of patchouli, 7-13 parts of raw malts, and 3.5-6.5 parts of cardamon. The drug is precise and appropriate in compatibility and less in drug flavor, ensures the drug efficacy, reduces side effects, and can effectively treat the duodenal ulcer, and a new administration selection is provided for clinical administration.
Description
Technical field
The present invention relates to the purposes of a kind of compound Rohoodiola compositions in the medicine of preparation treatment duodenal ulcer.
Background technology
Stomach duodenum ulcer refers to the circular or oval full-thickness defects of the limitation of Grastiodudenal mucosa, and muscularis mucosae is penetrated, and inevitably leaves fibrous scar after healing, and surface is covered by one deck epithelium, and muscularis mucosae can not be regenerated.It is because many reasons causes that gastric acid, pepsin self-digestion or the gastric mucosal barrier to gastric mucosa is destroyed that its cause of disease sums up.Think that in recent years formation and the gastric Helicobacter pylori infection of ulcer also have important relationship.
Chronic erosive gastritis, claims again the indigestion symptoms such as general rarely seen glutted, the pantothenic acid after meal of gastritis verrucosa or varioliform gastritis, belch, irregularities stomachache.There are multiple excipuliforms in Stomach in Patients mucosa, expands folded shape or pimple sample protuberance, diameter 5～10mm, and the visible mucomembranous defect in top or umbilicus sample depression, there is erosion at center, and protuberance is many without blush around, but normal with the similar erythema of size, with gastric antrum, portion is common.
The medicine of the above-mentioned disease of current treatment mostly is chemical drugs, and it is expensive, and side effect is large, and healing required time is long.Therefore, urgent need one is economical and practical, toxic and side effects is low, and the medicine of the above-mentioned disease of energy rapid healing.
And Chinese medicine aspect treatment of chronic diseases one to all playing an important role.Report, with Concha Arcae 75% and Radix Glycyrrhizae 25%, red in pulv, treatment gastric and duodenal ulcers, cure rate reaches 76% (" Chinese medicine voluminous dictionary " second edition, Shanghai science tech publishing house, in March, 2006,548th～549 pages); Also there is people to use Os Sepiae (life) 250g, Concha Arcae (calcined) 250g, Radix Et Rhizoma Rhei 200g, Radix Glycyrrhizae Preparata 200g, grinds to the powder, and boiled water is taken after mixing it with water after meal, each 15g, every day 3～4 times, be used for the treatment of peptic ulcer (Gu Linjiang, Cuttlefish Bone Powder for Peptic Ulcer, journal of shanghai Chinese medicine, 9 phases of calendar year 2001.Also there is people to treat peptic ulcer with Fructus Amomi Rotundus 10g, Rhizoma Atractylodis Macrocephalae 20g, Poria 20g, Herba Pogostemonis 15g, Herba Taraxaci 15g, Radix Ginseng 5g, Folium Perillae 10g, Semen Armeniacae Amarum 10g, Semen Coicis 20g, Herba Artemisiae Scopariae 15g, there is good therapeutic effect.
Summary of the invention
The object of the present invention is to provide the purposes of a kind of compound Rohoodiola compositions in the medicine of preparation treatment duodenal ulcer.
The invention provides the purposes of following compound Rohoodiola compositions in the medicine of preparation treatment duodenal ulcer; This medicine be the preparation being prepared from by the crude drug of following weight proportion:
Radix Rhodiolae 4.2-7.2 part, Poria 14-26 part, Herba Taraxaci 10.5-19.5 part, Herba Artemisiae Scopariae 10.5-19.5 part, Rhizoma Atractylodis Macrocephalae 10.5-19.5 part, Herba Pogostemonis 7-13 part, Fructus Hordei Germinatus 7-13 part, Fructus Amomi Rotundus 3.5-6.5 part.
Further, this medicine is the preparation being prepared from by the crude drug of following weight proportion:
Radix Rhodiolae 5-7 part, Poria 18-22 part, Herba Taraxaci 13-17 part, Herba Artemisiae Scopariae 13-17 part, Rhizoma Atractylodis Macrocephalae 13-17 part, Herba Pogostemonis 8-12 part, Fructus Hordei Germinatus 8-12 part, Fructus Amomi Rotundus 4-6 part.
Preferably, this medicine is the preparation being prepared from by the crude drug of following weight proportion:
6 parts of Radix Rhodiolaes, 20 parts, Poria, 15 parts of Herba Taraxacis, 15 parts of Herba Artemisiae Scopariaes, 15 parts of the Rhizoma Atractylodis Macrocephalaes, 10 parts of Herba Pogostemonis, 10 parts of Fructus Hordei Germinatus, 5 parts, Fructus Amomi Rotundus.
Wherein, described Fructus Amomi Rotundus is Fructus Amomi Rotundus.
Wherein, described preparation is slow releasing preparation or controlled release preparation.
In the present invention, Radix Rhodiolae, is dry root and the rhizome of crassulaceae plants Radix Rhodiolae Rhodiola crenulata (Hool.f.et Thoms.) H.Ohba.Sweet, bitter, flat, return lung, heart channel, benefiting QI for activating blood circulation, promotes blood circulation and relievings asthma.For blood stasis due to qi deficiency, obstruction of qi in the chest and cardialgia, apoplectic hemiplegia, asthenia asthma.
Herba Artemisiae Scopariae is that the quadrate part dryly of feverfew Artemisia scoparia Waldst. et Kit. Artemisia scoparia Waldst.Et Kit. or Herba Artemisiae Scopariae Artemisia capillaries Thunb. divides.Bitter, pungent, be slightly cold, return spleen, stomach, liver, gallbladder meridian.Eliminating damp-heat, promoting the function of the gallbladder to alleviate jaundice.For jaundice oliguria, hygropyrexia heat-damp in summer, eczema pruritus.
The Rhizoma Atractylodis Macrocephalae is the dry rhizome of feverfew Rhizoma Atractylodis Macrocephalae Atractylodes macrocephala Koidz..Bitter, sweet, temperature, returns spleen, stomach warp.Invigorating the spleen and benefiting QI, dampness diuretic, hidroschesis, antiabortive.For insufficiency of the spleen lack of appetite, abdominal distention is had loose bowels, phlegm retention vertigo and palpitation, edema, spontaneous perspiration, frequent fetal movement.
Poria is the dry sclerotia of On Polyporaceae Poria Poria cocos (Schw.) Wolf.Sweet, light, flat.GUIXIN, lung, spleen, kidney channel.Promoting diuresis to eliminate damp pathogen, spleen invigorating, mind calming.For edema oliguria, phlegm retention vertigo and palpitation, insufficiency of the spleen lack of appetite, have loose bowels in loose stool, irritability, palpitation with fear insomnia.
Herba Taraxaci is Herba Taraxaci Taraxacum mongolicum Hand.Mazz, alkali ground Herba Taraxaci Taraxacum borealisinense Kitam. or the dry herb that belongs to several plants together.Bitter, sweet, cold.Return liver, stomach warp.Heat-clearing and toxic substances removing, dispersing swelling and dissipating binds, inducing diuresis for treating stranguria syndrome.For furuncle swelling toxin, acute mastitis, scrofula, conjunctival congestion, pharyngalgia, lung abscess, acute appendicitis, jaundice due to damp-heat, the puckery pain of pyretic stranguria.
Herba Pogostemonis is that the quadrate part dryly of labiate Herba Pogostemonis Pogostemon cablin (Blanco) Benth. divides.Pungent, tepor.Return spleen, stomach, lung meridian.Eliminating turbid pathogen with aromatics, and middle preventing or arresting vomiting, deliver expelling summer-heat.For turbid damp obstructing in middle-JIAO, the vomiting of gastral cavity painful abdominal mass, heat-damp in summer exterior syndrome, hygropyrexia is from the beginning of, heating asthenia, uncomfortable in chestly do not relax, and cold-damp is closed summer-heat, and stomachache is vomited and diarrhoea, nasosinusitis headache.
Compatibility of drugs of the present invention is precise and appropriate, and flavour of a drug are less, has not only ensured drug effect to have reduced side effect, can effectively treat duodenal ulcer, selects for clinical application provides a kind of new medication.
Detailed description of the invention
The preparation of embodiment 1 medicine of the present invention
Get Poria 20g, Herba Taraxaci 15g, Herba Artemisiae Scopariae 15g, Rhizoma Atractylodis Macrocephalae 15g, Herba Pogostemonis 10g, Fructus Hordei Germinatus 10g, Radix Rhodiolae 6g, Fructus Amomi Rotundus 5g; First add 4 times of water gagings to soak 10 minutes, then decoct with water 2 times, each 20 minutes, add water 10 times at every turn and measure, filter, merge after decocting liquid, obtain medicine decoction of the present invention.
The preparation of embodiment 2 medicines of the present invention
Poria 20g, Herba Taraxaci 15g, Herba Artemisiae Scopariae 15g, Rhizoma Atractylodis Macrocephalae 15g, Herba Pogostemonis 10g, Fructus Hordei Germinatus 10g, Radix Rhodiolae 6g, Fructus Amomi Rotundus 5g; Decoct with water 3 times, add for the first time 10 times of water gagings and decoct 5 minutes, add for the second time 8 times of water gagings and decoct 10 minutes, add for the third time 8 times of water gagings and decoct 15 minutes, filter, merge after decocting liquid, concentrated, then add proper starch, and granulate, obtain medicinal granule of the present invention.
The preparation of embodiment 3 medicines of the present invention
Get Poria 20g, Herba Taraxaci 15g, Herba Artemisiae Scopariae 15g, Rhizoma Atractylodis Macrocephalae 15g, Herba Pogostemonis 10g, Fructus Hordei Germinatus 10g, Radix Rhodiolae 6g, Fructus Amomi Rotundus 5g; First add 10 times of amount 70% alcoholic solution reflux, extract, 1 time, extract 1 hour, filter, filtrate is for subsequent use, and filtering residue again water decocts 2 times, and 8 times of amounts add water at every turn, each decoction 20 minutes, merge after ethanol extract and decocting liquid, concentrated, then add appropriate microcrystalline Cellulose and dextrin and Radix Rhodiolae powder, after granulation, add appropriate magnesium stearate, tabletting, obtains medicinal tablet of the present invention again.
The preparation of embodiment 4 medicines of the present invention
Get Poria 18g, Herba Taraxaci 17g, Herba Artemisiae Scopariae 17g, Rhizoma Atractylodis Macrocephalae 17g, Herba Pogostemonis 12g, Fructus Hordei Germinatus 12g, Radix Rhodiolae 7g, Fructus Amomi Rotundus 6g; First add 4 times of water gagings to soak 10 minutes, then decoct with water 2 times, each 20 minutes, add water 10 times at every turn and measure, filter, merge after decocting liquid, obtain medicine decoction of the present invention.
The preparation of embodiment 5 medicines of the present invention
Get Poria 22g, Herba Taraxaci 13g, Herba Artemisiae Scopariae 13g, Rhizoma Atractylodis Macrocephalae 13g, Herba Pogostemonis 8g, Fructus Hordei Germinatus 8g, Radix Rhodiolae 5g, Fructus Amomi Rotundus 4g; After pulverizing, cross 80 mesh sieves, then add microcrystalline Cellulose, after mixing, encapsulated, obtain medicine capsule of the present invention.
Further show beneficial effect of the present invention by concrete test example below.
The treatment of test example 1 medicine of the present invention to duodenal ulcer
Duodenal ulcer diagnostic criteria: epigastrium dull pain, causalgia, distending pain or severe pain, also can be only dull pain discomfort in the time of hunger, or there is rest pain under slight or moderate xiphoid-process, can be alleviated by antacid or feed, early within 1～3 hour after the meal, start to occur upper abdominal pain, will continue to lunch if do not taken medicine or taking food after, just alleviate, food also must have meal to alleviate for latter 2～4 hours again bitterly.Endoscopy, thick fur and filth can have petechia, sludged blood on it, the obvious congestion and edema erosion of mucosa around; Or tongue is still thicker, around mucosal inflammation edema alleviates, and red re-epithelialize (active stage) can appear in ulcer edge.Accept altogether 27 examples for medical treatment, endoscopy is confirmed as duodenal ulcer.
Therapeutic Method: get the decoction that embodiment 1 prepares, every bu is taken for 3 times, period in a medicine, avoids eating anything raw or cold, maror.
Criterion of cure: pain disappears, endoscopy, white fur disappears, and replaces red epithelium and cicatrix; Or re-epithelialize redness disappears, cicatrix color white (being cicatricial phase).Take medicine continuously by Therapeutic Method, treat 15～20 days, cure 27 examples, account for 100% of total case.
Model case 1
To certain, man, 22 years old, stomach felt there is feeling of repletion, occurs upper abdominal pain after meal about 2 hours, upper abdomen dull pain when rise morning, after meal or close on ante cibum and have belch phenomenon, anorexia, loses weight; Through endoscopy, confirm as duodenal ulcer.
Take medicine after 3 days by test example 1 method, feeling of repletion, belch phenomenon are alleviated, and after 7 days, it is suitable with normal period that appetite has recovered, and swollen sense, belch phenomenon disappear.After 30 days, through gastroscopy, ulcer surface heals, and conscious appetite, stomach feel good, and body weight is gone up.
The therapeutical effect of test example 2 pharmaceutical composition of the present invention to duodenal ulcer rat model
Get SD rat, male and female half and half, after anesthesia, by improvement Okabe method, get the glass tubing of internal diameter 3mm, vertical flicking on 0.5cm place duodenum antetheca serosal surface, injects 70% acetic acid 0.075ml, after 15s under pylorus in this pipe, sucking-off acetic acid, closes abdomen, obtains duodenal ulcer model.Postoperative 4 days, rat is divided into model group (10mlkg
-1distilled water), pharmaceutical composition of the present invention senior middle school low dose group (be followed successively by 20,40,80g crude drug/kg body weight), contrast groups A (20g crude drug/kg body weight), contrast groups B (20g crude drug/kg body weight), positive drug omeprazole group (pressing quantity converts), gavage, after 7 days, is put to death rat respectively, takes out duodenum and observes ulcer inhibition rate.
Pharmaceutical composition of the present invention is prepared by embodiment 1;
The preparation method of contrast groups A medicine is as follows:
Get Fructus Amomi Rotundus 10g, Rhizoma Atractylodis Macrocephalae 20g, Poria 20g, Herba Pogostemonis 15g, Herba Taraxaci 15g, Radix Ginseng 5g, Folium Perillae 10g, Semen Armeniacae Amarum 10g, Semen Coicis 20g, Herba Artemisiae Scopariae 15g; First add 4 times of water gagings to soak 10 minutes, then decoct with water 2 times, each 20 minutes, add water 10 times at every turn and measure, filter, merge after decocting liquid, obtain contrast groups A decoction.
The preparation method of contrast groups B medicine is as follows:
20 parts of Semen Coiciss, 20 parts of Semen Benincasaes, 15 parts of Herba Artemisiae Scopariaes, 15 parts of the Rhizoma Atractylodis Macrocephalaes, 10 parts of Folium Perillaes, 10 parts of Semen Armeniacae Amarums, 10 parts of Semen Lablab Albums, 10 parts of Semen Myristicaes, 10 parts of the Radixs Astragali, 5 parts of Radix Ginsengs, 5 parts of Fructus Forsythiaes.First add 4 times of water gagings to soak 10 minutes, then decoct with water 2 times, each 20 minutes, add water 10 times at every turn and measure, filter, merge after decocting liquid, obtain contrast groups B decoction.
The results are shown in Table 1.
Table 1
Note: compared with model group, * is p < 0.05, and * * is p < 0.01; Compared with contrast groups A, △ is p < 0.05; Compared with contrast groups B, a is p < 0.05.
As shown in Table 1, pharmaceutical composition of the present invention, can effectively treat duodenal ulcer, simultaneously, compared with contrast groups A, although ingredients is similar,, the drug activity of pharmaceutical composition of the present invention under Isodose is obviously better than contrast groups A (p < 0.05); Compared with contrast groups B, the drug activity under Isodose is suitable, but present composition flavour of a drug still less.Above-mentioned test shows, pharmaceutical composition compatibility of the present invention is precise and appropriate, has brought into play synergistic function.
Test example 3 contrasts with the clinical drug effect of contrast groups B
Except above-mentioned case, other cases totally 23 people that also accepted duodenal ulcer for medical treatment, all use following prescription to treat: 20 parts of Semen Coiciss, 20 parts of Semen Benincasaes, 15 parts of Herba Artemisiae Scopariaes, 15 parts of the Rhizoma Atractylodis Macrocephalaes, 10 parts of Folium Perillaes, 10 parts of Semen Armeniacae Amarums, 10 parts of Semen Lablab Albums, 10 parts of Semen Myristicaes, 10 parts of the Radixs Astragali, 5 parts of Radix Ginsengs, 5 parts of Fructus Forsythiaes.
Treat after 10 days, more than 90% patient thinks that epigastric discomfort slows down or disappears, and appetite improves, and shows that its peptic ulcer has taken a favorable turn or healing trend, but most of patients is after medication, flatulence in the lower abdomen, and empty respectful number of times obviously increases.
And adopt medicine of the present invention to treat, there is not the side effect such as flatulence in the lower abdomen in patient, and cure rate is high, shows that the present invention is changing after the flavour of a drug composition and medical material consumption of prescription, not only ensured curative effect, also reduced side effect.
In sum, compatibility of drugs of the present invention is precise and appropriate, and flavour of a drug are less, has not only ensured drug effect to have reduced side effect, can effectively treat duodenal ulcer, selects for clinical application provides a kind of new medication.
Claims (4)
1. the purposes of following compound Rohoodiola compositions in the medicine of preparation treatment duodenal ulcer; This medicine is the preparation being prepared from by the crude drug of following weight proportion:
Radix Rhodiolae 4.2-7.2 part, Poria 14-26 part, Herba Taraxaci 10.5-19.5 part, Herba Artemisiae Scopariae 10.5-19.5 part, Rhizoma Atractylodis Macrocephalae 10.5-19.5 part, Herba Pogostemonis 7-13 part, Fructus Hordei Germinatus 7-13 part, Fructus Amomi Rotundus 3.5-6.5 part.
2. purposes according to claim 1, is characterized in that: this medicine is the preparation being prepared from by the crude drug of following weight proportion:
Radix Rhodiolae 5-7 part, Poria 18-22 part, Herba Taraxaci 13-17 part, Herba Artemisiae Scopariae 13-17 part, Rhizoma Atractylodis Macrocephalae 13-17 part, Herba Pogostemonis 8-12 part, Fructus Hordei Germinatus 8-12 part, Fructus Amomi Rotundus 4-6 part.
3. purposes according to claim 2, is characterized in that: this medicine is the preparation being prepared from by the crude drug of following weight proportion:
6 parts of Radix Rhodiolaes, 20 parts, Poria, 15 parts of Herba Taraxacis, 15 parts of Herba Artemisiae Scopariaes, 15 parts of the Rhizoma Atractylodis Macrocephalaes, 10 parts of Herba Pogostemonis, 10 parts of Fructus Hordei Germinatus, 5 parts of Fructus Amomi Rotunduss.
4. according to the purposes described in claim 1-3 any one, it is characterized in that: described preparation is slow releasing preparation or controlled release preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310260997.XA CN103272170B (en) | 2013-06-26 | 2013-06-26 | Application of rhodiola rosea compound composite in preparing drug for treating duodenal ulcer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310260997.XA CN103272170B (en) | 2013-06-26 | 2013-06-26 | Application of rhodiola rosea compound composite in preparing drug for treating duodenal ulcer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103272170A CN103272170A (en) | 2013-09-04 |
| CN103272170B true CN103272170B (en) | 2014-08-13 |
Family
ID=49054509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310260997.XA Active CN103272170B (en) | 2013-06-26 | 2013-06-26 | Application of rhodiola rosea compound composite in preparing drug for treating duodenal ulcer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103272170B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104138550A (en) * | 2014-08-12 | 2014-11-12 | 徐继锋 | Preparation method of medicine for treating peptic ulcers |
| CN105214033A (en) * | 2015-09-30 | 2016-01-06 | 成都恒凌科技有限公司 | The purposes of a kind of pharmaceutical composition in the medicine of preparation treatment duodenal ulcer |
| CN105214032A (en) * | 2015-09-30 | 2016-01-06 | 成都恒凌科技有限公司 | The solid dispersion tablet for the treatment of peptic ulcer |
| CN105250944A (en) * | 2015-09-30 | 2016-01-20 | 成都恒凌科技有限公司 | Capsules for treating peptic ulcers |
| CN105288530A (en) * | 2015-09-30 | 2016-02-03 | 成都恒凌科技有限公司 | Capsule for treating peptic ulcer and preparation method of capsule |
| CN105233200A (en) * | 2015-09-30 | 2016-01-13 | 成都恒凌科技有限公司 | Tablets for treating digestive ulcer |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101757542A (en) * | 2010-04-07 | 2010-06-30 | 泰一和浦（北京）中医药研究院有限公司 | Traditional Chinese medicine composition for treating colonitis and preparation method |
| CN101785835A (en) * | 2010-02-28 | 2010-07-28 | 泰一和浦（北京）中医药研究院有限公司 | Traditional Chinese medicine combination and preparation method thereof for chronic enteritis treatment |
-
2013
- 2013-06-26 CN CN201310260997.XA patent/CN103272170B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101785835A (en) * | 2010-02-28 | 2010-07-28 | 泰一和浦（北京）中医药研究院有限公司 | Traditional Chinese medicine combination and preparation method thereof for chronic enteritis treatment |
| CN101757542A (en) * | 2010-04-07 | 2010-06-30 | 泰一和浦（北京）中医药研究院有限公司 | Traditional Chinese medicine composition for treating colonitis and preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103272170A (en) | 2013-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103272169B (en) | Application of rhodiola rosea compound composite in treating erosive gastritis | |
| CN103285309B (en) | Rhodiola rosea compound composition for treating peptic ulcer | |
| CN103285310B (en) | Use of rhodiola rosea compound composition in preparing medicine for curing gastric ulcer | |
| CN103272170B (en) | Application of rhodiola rosea compound composite in preparing drug for treating duodenal ulcer | |
| CN105233202A (en) | Preparation method of drug for treating peptic ulcers and extractive prepared according to preparation method | |
| CN104138550A (en) | Preparation method of medicine for treating peptic ulcers | |
| CN102416121B (en) | Application of medicinal composition in preparation of medicaments for treating gastric ulcer | |
| CN105214032A (en) | The solid dispersion tablet for the treatment of peptic ulcer | |
| CN102430073B (en) | Medicinal composition for treating peptic ulcer | |
| CN102416120B (en) | Application of medicinal composition in preparation of medicament for treating erosive gastritis | |
| CN105250946A (en) | Solid dispersion for treating peptic ulcers | |
| CN105214035A (en) | One treats peptic ulcer tablet and preparation method thereof | |
| CN105214031A (en) | A kind of water extract granule for the treatment of peptic ulcer | |
| CN105233201A (en) | Solid dispersible granules for treating peptic ulcers | |
| CN104138551A (en) | Application of pharmaceutical composition in preparation of medicaments for treating duodenal ulcer | |
| CN105214037A (en) | The solid dispersal capsule for the treatment of peptic ulcer | |
| CN104138553A (en) | Pharmaceutical composition for treating peptic ulcer | |
| CN102416122B (en) | Application of medicinal composition in preparation of medicaments for treating duodenal ulcer | |
| CN105250951A (en) | Preparing method for medicine for treating peptic ulcer | |
| CN105194608A (en) | Micro-powder capsule for treating peptic ulcers | |
| CN105214030A (en) | The purposes of a kind of pharmaceutical composition in the medicine of preparation treatment gastric ulcer | |
| CN104138552A (en) | Application of pharmaceutical composition in preparation of medicaments for treating gastric ulcer | |
| CN104147453A (en) | Use of medicinal composition in preparation of erosive gastritis treatment medicines | |
| CN105194609A (en) | Pharmaceutical composition for treating peptic ulcers | |
| CN105250942A (en) | Application of medicine composition in preparation of medicine for treating erosive gastritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230922 Address after: Room 1218-19, Building 3, No. 1366 Hongfeng Road, Huzhou Economic and Technological Development Zone, Huzhou City, Zhejiang Province, 313098 Patentee after: Zhonghe baosang Biotechnology Co.,Ltd. Address before: 810001 No. 59 Xiguan Street, Xining, Qinghai Patentee before: Northwest Institute of Plateau Biology, Chinese Academy of Sciences |
|
| TR01 | Transfer of patent right | ||
| EE01 | Entry into force of recordation of patent licensing contract | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20130904 Assignee: Zhonghe Baosang (Huzhou) Food Production Co.,Ltd. Assignor: Zhonghe baosang Biotechnology Co.,Ltd. Contract record no.: X2024980013691 Denomination of invention: The use of a compound composition of Rhodiola rosea in the preparation of drugs for treating duodenal ulcers Granted publication date: 20140813 License type: Common License Record date: 20240902 Application publication date: 20130904 Assignee: Zhonghe Baosang (Huzhou) E commerce Co.,Ltd. Second Branch Assignor: Zhonghe baosang Biotechnology Co.,Ltd. Contract record no.: X2024980013389 Denomination of invention: The use of a compound composition of Rhodiola rosea in the preparation of drugs for treating duodenal ulcers Granted publication date: 20140813 License type: Common License Record date: 20240830 |
|
| EE01 | Entry into force of recordation of patent licensing contract | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20130904 Assignee: Zhonghe Baosang (Huzhou) E commerce Co.,Ltd. Fourth Branch Assignor: Zhonghe baosang Biotechnology Co.,Ltd. Contract record no.: X2024980014267 Denomination of invention: The use of a compound composition of Rhodiola rosea in the preparation of drugs for treating duodenal ulcers Granted publication date: 20140813 License type: Common License Record date: 20240911 Application publication date: 20130904 Assignee: Zhonghe Baosang (Huzhou) E commerce Co.,Ltd. Third Branch Assignor: Zhonghe baosang Biotechnology Co.,Ltd. Contract record no.: X2024980014264 Denomination of invention: The use of a compound composition of Rhodiola rosea in the preparation of drugs for treating duodenal ulcers Granted publication date: 20140813 License type: Common License Record date: 20240911 Application publication date: 20130904 Assignee: Zhejiang Zhongtian Youth Biotechnology Co.,Ltd. Assignor: Zhonghe baosang Biotechnology Co.,Ltd. Contract record no.: X2024980014257 Denomination of invention: The use of a compound composition of Rhodiola rosea in the preparation of drugs for treating duodenal ulcers Granted publication date: 20140813 License type: Common License Record date: 20240911 Application publication date: 20130904 Assignee: Zhonghe Baosang (Huzhou) Marketing Management Co.,Ltd. Assignor: Zhonghe baosang Biotechnology Co.,Ltd. Contract record no.: X2024980014290 Denomination of invention: The use of a compound composition of Rhodiola rosea in the preparation of drugs for treating duodenal ulcers Granted publication date: 20140813 License type: Common License Record date: 20240911 Application publication date: 20130904 Assignee: Huzhou Baosang Natural product Technology Research Institute Co.,Ltd. Assignor: Zhonghe baosang Biotechnology Co.,Ltd. Contract record no.: X2024980014285 Denomination of invention: The use of a compound composition of Rhodiola rosea in the preparation of drugs for treating duodenal ulcers Granted publication date: 20140813 License type: Common License Record date: 20240911 Application publication date: 20130904 Assignee: Huzhou Qimeng Mutual Entertainment Cultural Media Co.,Ltd. Assignor: Zhonghe baosang Biotechnology Co.,Ltd. Contract record no.: X2024980014281 Denomination of invention: The use of a compound composition of Rhodiola rosea in the preparation of drugs for treating duodenal ulcers Granted publication date: 20140813 License type: Common License Record date: 20240911 Application publication date: 20130904 Assignee: Huzhou Palm Jump Network Technology Co.,Ltd. Assignor: Zhonghe baosang Biotechnology Co.,Ltd. Contract record no.: X2024980014280 Denomination of invention: The use of a compound composition of Rhodiola rosea in the preparation of drugs for treating duodenal ulcers Granted publication date: 20140813 License type: Common License Record date: 20240911 Application publication date: 20130904 Assignee: Zhonghe Baosang (Huzhou) E commerce Co.,Ltd. Sales Branch Assignor: Zhonghe baosang Biotechnology Co.,Ltd. Contract record no.: X2024980014270 Denomination of invention: The use of a compound composition of Rhodiola rosea in the preparation of drugs for treating duodenal ulcers Granted publication date: 20140813 License type: Common License Record date: 20240911 |
|
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20130904 Assignee: Zhonghe Baosang (Huzhou) Marketing Management Co.,Ltd. Wuxing Branch Assignor: Zhonghe baosang Biotechnology Co.,Ltd. Contract record no.: X2024980014386 Denomination of invention: The use of a compound composition of Rhodiola rosea in the preparation of drugs for treating duodenal ulcers Granted publication date: 20140813 License type: Common License Record date: 20240919 Application publication date: 20130904 Assignee: Zhonghe Baosang (Huzhou) E-commerce Co.,Ltd. Assignor: Zhonghe baosang Biotechnology Co.,Ltd. Contract record no.: X2024980014385 Denomination of invention: The use of a compound composition of Rhodiola rosea in the preparation of drugs for treating duodenal ulcers Granted publication date: 20140813 License type: Common License Record date: 20240919 |